Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Imeglimin: Completed Phase IIb enrollment

    Poxel S.A. (Euronext:POXEL), Lyon, France Product: Imeglimin Business: Endocrine/Metabolic Molecular target: NA Description: Inhibitor of mitochondrial permeability transition pore (PTP) opening Indication: Treat Type …

    Published on 7/18/2016
  • Lidocaine vaginal gel: Completed Phase IIb enrollment

    Juniper Pharmaceuticals Inc. (NASDAQ:JNP), Boston, Mass. Product: Lidocaine vaginal gel (COL-1077) Business: Neurology Molecular target: Sodium channel Description: Lidocaine bioadhesive 10% vaginal gel Indication: …

    Published on 7/18/2016
  • ONCOS-102: Phase Ib/II started

    Targovax A/S, Oslo, Norway Product: ONCOS-102 (formerly CGTG-102) Business: Cancer Molecular target: NA Description: Modified tumor-targeted human serotype 5/3 adenovirus carrying the gene for GM-CSF Indication: Treat …

    Published on 7/18/2016
  • QGC101: Phase IIa started

    Quantum Genomics Corp. (Euronext:ALQGC), Paris, France Product: QGC101 Business: Cardiovascular Molecular target: Glutamyl aminopeptidase (ENPEP) Description: Glutamyl aminopeptidase (ENPEP) inhibitor Indication: Treat …

    Published on 7/18/2016
  • TD-6450: Phase IIa started

    Trek Therapeutics PBC, Cambridge, Mass. Theravance Biopharma Inc. (NASDAQ:TBPH), South San Francisco, Calif. Product: TD-6450 Business: Infectious Molecular target: HCV NS5A protein Description: Multivalent HCV NS5A …

    Published on 7/18/2016
  • Tenapanor: Phase IIb amended

    Ardelyx Inc. (NASDAQ:ARDX), Fremont, Calif. Product: Tenapanor (AZD1722, RDX5791) Business: Endocrine/Metabolic Molecular target: Solute carrier family 9 sodium hydrogen exchanger member 3 (SLC9A3) (NHE3) Description: …

    Published on 7/18/2016
  • ZYN002: Phase II started

    Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE), Radnor, Pa. Product: ZYN002 Business: Neurology Molecular target: NA Description: Synthetic cannabidiol (CBD) formulated as a transdermal gel Indication: Treat refractory …

    Published on 7/18/2016
  • 19-28z CAR T cells: Phase II halted

    Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Product: 19-28z CAR T cells (JCAR015) Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) …

    Published on 7/11/2016
  • AADvac1: Phase II started

    Axon Neuroscience SE, Larnaca, Cyprus Product: AADvac1 Business: Neurology Molecular target: NA Description: Active vaccine containing synthetic peptide derived from microtubule-associated protein tau (tau; MAPT; FTDP-…

    Published on 7/11/2016
  • BC8-I-131: Phase III started

    Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y. Product: BC8-I-131, Iomab-B Business: Cancer Molecular target: CD45 Description: Anti-CD45 mAb (BC8) labeled with iodine-131 Indication: Improve outcomes of …

    Published on 7/11/2016
  • BNC210: Completed Phase II enrollment

    Bionomics Ltd. (ASX:BNO; OTCQX:BNOEF), Thebarton, Australia Product: BNC210 Business: Neurology Molecular target: Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Description: Negative allosteric modulator of nicotinic…

    Published on 7/11/2016
  • CA-170: Phase I started

    Aurigene Discovery Technologies Ltd., Bangalore, India Curis Inc. (NASDAQ:CRIS), Lexington, Mass. Product: CA-170 (formerly AUPM-170) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (…

    Published on 7/11/2016
  • CMV eVLP: Phase I started

    VBI Vaccines Inc. (NASDAQ:VBIV; TSX:VBV), Cambridge, Mass. Product: CMV eVLP (VBI-1501A) Business: Infectious Molecular target: NA Description: Vaccine based on VBIs enveloped virus-like particle (eVLP) platform …

    Published on 7/11/2016
  • COH29: Phase I started

    Novonco Therapeutics Inc., Los Angeles, Calif. City of Hope, Duarte, Calif. Product: COH29 Business: Cancer Molecular target: Ribonucleotide reductase Description: Small molecule ribonucleotide reductase inhibitor …

    Published on 7/11/2016
  • CollaRx gentamicin topical: Completed Phase III enrollment

    Innocoll Holdings plc (NASDAQ:INNL), Athlone, Ireland Product: CollaRx gentamicin topical, Cogenzia (INL-002) Business: Infectious Molecular target: Ribosomal 30S subunit Description: Topical bioresorbable collagen …

    Published on 7/11/2016
  • CollaRx gentamicin topical: Completed Phase III enrollment

    Innocoll Holdings plc (NASDAQ:INNL), Athlone, Ireland Product: CollaRx gentamicin topical, Cogenzia (INL-002) Business: Infectious Molecular target: Ribosomal 30S subunit Description: Topical bioresorbable collagen …

    Published on 7/11/2016
  • Durvalumab: Phase II started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Durvalumab (MEDI4736) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting PD-L1 …

    Published on 7/11/2016
  • Epacadostat: Phase III started

    Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Product: Epacadostat (INCB24360) Business: Cancer Molecular target: Indoleamine 2,3-dioxygenase 1 (IDO1) Description: Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor …

    Published on 7/11/2016
  • Fentanyl iontophoretic transdermal system: Phase III started

    SymBio Pharmaceuticals Ltd. (JASDAQ:4582), Tokyo, Japan The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Fentanyl iontophoretic transdermal system (Ionsys) (…

    Published on 7/11/2016
  • Fosbretabulin: Phase II/III started

    Mateon Therapeutics Inc. (NASDAQ:MATN), South San Francisco, Calif. Product: Fosbretabulin (Combretastatin A4P, Zybrestat)) (CA4P) Business: Cancer Molecular target: Tubulin Description: A4 prodrug phosphatase-activated…

    Published on 7/11/2016
  • GBT440: Phase IIa started

    Global Blood Therapeutics Inc. (NASDAQ:GBT), South San Francisco, Calif. Product: GBT440 Business: Hematology Molecular target: Hemoglobin Description: Allosteric modifier of hemoglobin oxygen affinity Indication: Treat…

    Published on 7/11/2016
  • Human neural stem cells: Phase II discontinued

    StemCells Inc. (NASDAQ:STEM), Newark, Calif. Product: Human neural stem cells (HuCNS-SC) Business: Neurology Molecular target: Not applicable Description: Purified human neural stem cells Indication: Treat cervical …

    Published on 7/11/2016
  • INCAGN1876: Phase I/II started

    Agenus Inc. (NASDAQ:AGEN), Lexington, Mass. Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Product: INCAGN1876 Business: Cancer Molecular target: Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related …

    Published on 7/11/2016
  • INOpulse: Phase III started

    Bellerophon Therapeutics Inc. (NASDAQ:BLPH), Hampton, N.J. Mallinckrodt plc (NYSE:MNK), St. Louis, Mo. Product: INOpulse Business: Cardiovascular Molecular target: Not applicable Description: Inhaled nitric oxide (NO) …

    Published on 7/11/2016
  • ITI-007: Completed Phase III enrollment

    Intra-Cellular Therapies Inc. (NASDAQ:ITCI), New York, N.Y. Product: ITI-007 Business: Neurology Molecular target: Serotonin (5-HT2A) receptor; Dopamine receptor Description: Dual serotonin (5-HT2A) receptor antagonist …

    Published on 7/11/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993